Therapeutic Effect of Yttrium Oxide Nanoparticles for the Treatment of Fulminant Hepatic Failure

Abstract

<b>Aim:</b> To explore the potential therapeutic effect of yttrium oxide nanoparticles (Y₂O₃ NPs) on fulminant hepatic failure. <b>Materials & methods:</b> RAW264.7 cells and a lipopolysaccharide/D-galactosamine-induced hepatic failure murine model were used to assess the effects of Y₂O₃ NPs. <b>Results:</b> Y₂O₃ NPs exhibited anti-inflammatory activity by scavenging cellular reactive oxygen species and dampening reactive oxygen species-mediated NF-κB activation <i>in vitro</i>. A single intraperitoneal administration of Y₂O₃ NPs (30 mg/kg) enhanced hepatic antioxidant status and reduced oxidative stress and inflammatory response in lipopolysaccharide/galactosamine-induced mice. Y₂O₃ NPs also attenuated hepatic NF-κB activation, cell apoptosis and liver injury. <b>Conclusion:</b> Y₂O₃ NP administration could be used as a novel therapeutic strategy for treating fulminant hepatic failure and oxidative stress-related diseases.